Merck & Co., Inc. MRK SPX
Company Overview
Merck & Co., Inc. operates as a healthcare company worldwide. It offers human health pharmaceutical for various areas under the Keytruda, Keytruda Qlex, Welireg, Gardasil, ProQuad, M-M-R II, Varivax, Vaxneuvance, Capvaxive, RotaTeq, Pneumovax 23, Bridion, Prevymis, Dificid, Zerbaxa, Winrevair, Adempas/ Verquvo, Ohtuvayre, Lagevrio, Isentress/Isentress HD, Delstrigo, Pifeltro, Belsomra, Januvia, and Janumet brands. The company also provides veterinary pharmaceuticals, vaccines and health management solutions and services, such as livestock products under the Nuflor, Bovilis/Vista, Bovilis Cryptium, Banamine, Estrumate, Matrix, Resflor, Zuprevo, Revalor, Safe-Guard, M+Pac, Porcilis, Circumvent, Nobilis/Innovax, Paracox and Coccivac, Exzolt, Slice, Imvixa, Clynav, Aquavac/Norvax, Aquaflor, Flexolt brands; Allflex Livestock Intelligence solutions; and companion animal products under the Bravecto One-Month, Bravecto Injectable/Quantum, Bravecto TriUNO, Bravecto Plus, Sentinel Spectrum, Sentinel Flavor Tabs, Numelvi, Optimmune, Nobivac NXT, GilvetMab, Otomax, Mometamax, Mometamax Ultra, Posatex, Caninsulin/Vetsulin, Panacur, Safeguard, Regumate, Prestige, Scalibor/Exspot, Sure Petcare, and Home Again brands. It has development and commercialization agreement for three of Daiichi Sankyo's deruxtecan ADC candidates; AstraZeneca PLC to co-development and co-commercialize AstraZeneca's Lynparza products for multiple cancer types; licensed to develop, manufacture and commercialize LM-299, a novel investigational PD-1/VEGF bispecific antibody from LaNova; and collaboration agreement with Eisai Co., Ltd., Bayer AG, and Ridgeback Biotherapeutics LP, as well Moderna, Inc. Merck & Co., Inc. has strategic collaboration with Infinimmune, Inc. to discover and develop antibodies against multiple therapeutic targets. The company was founded in 1891 and is headquartered in Rahway, New Jersey.
Why Investors Should Care
Generates a return on equity of 18.9%, reflecting efficient use of shareholder capital.
Net profit has compounded at 10.0% per year over the last five years.
Operating margin of 38.6% supports profitability.
Offers a dividend yield of 2.86%.
Generates positive free cash flow, funding growth and shareholder returns internally.
Recent Developments
- Dec 2025 Revenue of $65.01B (+1.3% YoY); net profit $18.25B.
- Trailing 12 Months Year-on-year growth — revenue +4.9%, earnings +6.6%.
- 5-Year Trend Long-term compounding — revenue CAGR 5.6%, profit CAGR 10.0%.
Growth & Price Performance
Compounded Sales Growth
| 5 Years: | 5.64% |
| 1 Year: | 4.90% |
Compounded Profit Growth
| 5 Years: | 10.01% |
| 1 Year: | 6.64% |
Stock Price Performance
| 1 Year: | +49.18% |
| 6 Months: | +10.87% |
| 3 Months: | +1.25% |
| 1 Month: | +0.74% |
Highlights auto-generated from reported financials and price data; not investment advice. Verify with official filings before acting.
- Price vs 50-DMAAbove
- Price vs 200-DMAAbove
- RSI (14)47.15 · Neutral
P/E of 34.02 is above the sector median of 25.41 — pricier than peers.
Auto-generated from price history and fundamentals; not investment advice.
Price Chart
Technical Trend
Computed from daily close history using EMA cross, slope, and RSI signals.
Note: intraday data is not stored locally. “Hourly” uses the most recent 10 daily candles as a short-term proxy.
Fundamental Growth Charts
No fundamental data available for this stock.
Interactive charts for Revenue, Net Income, EBITDA, Free Cash Flow, EPS, ROE, ROCE, Gross/Net/Operating Margin and more — switch metric and period using the dropdowns above. CAGR is computed across the displayed window (quarterly CAGR is annualised). Visual growth charts make it easy to spot multi-year compounding trends at a glance — far faster than reading raw numbers in a table.
PROS
- Profit CAGR of 10.0% over 5 years.
- Attractive dividend yield of 2.86%.
- Generates positive free cash flow.
- In a confirmed uptrend (50-DMA above 200-DMA).
CONS
No notable concerns flagged.
* The pros and cons are auto-generated from financial metrics.
Valuation
Growth (CAGR)
Profitability & Returns
Balance Sheet & Liquidity
Ownership
Financial Snapshot
Peer comparison
Peer companies in the same sector (Healthcare).
| # | Name | CMP $ | P/E | Mkt Cap | Div Yld % | ROCE % | ROE % | Rev CAGR 5Y % | Profit CAGR 5Y % |
|---|---|---|---|---|---|---|---|---|---|
| 1 | MRK Merck & Co., Inc. SPX | 120.78 | 34.02 | $298.31B | 2.86% | - | 18.94% | 5.64% | 10.01% |
| 2 | LLY Eli Lilly and Company SPX | 1,152.54 | 41.02 | $1.03T | 0.61% | - | 107.46% | 7.20% | 11.41% |
| 3 | JNJ Johnson & Johnson SPX | 253.85 | 29.45 | $611.07B | 2.23% | 14.88% | 26.42% | 2.43% | 4.76% |
| 4 | ABBV AbbVie Inc. SPX | 244.78 | 119.40 | $432.48B | 3.04% | 10.47% | -129.24% | 1.75% | -29.06% |
| 5 | UNH UnitedHealth Group Incorporated SPX | 425.19 | 32.02 | $386.13B | 2.27% | 9.74% | 12.18% | 10.40% | 5.43% |
| 6 | AZN AstraZeneca PLC NDX | 164.50 | 24.81 | $255.12B | 1.77% | 15.97% | 23.48% | 9.82% | 45.96% |
| 7 | TMO Thermo Fisher Scientific Inc. SPX | 534.07 | 29.33 | $198.47B | 0.40% | 8.14% | 13.52% | 8.81% | 12.95% |
| 8 | AMGN Amgen Inc. NDXSPX | 355.25 | 24.69 | $191.73B | 2.84% | 18.02% | 101.32% | 11.77% | 5.58% |
| 9 | GILD Gilead Sciences, Inc. NDXSPX | 130.04 | 17.69 | $161.45B | 2.61% | 21.23% | 43.36% | 11.38% | 9.79% |
Financial Statements Quarterly Results · Profit & Loss · Balance Sheet · Cash Flows · Ratios
Quarterly Results
Figures in USD.
| Metric | Mar 2013 | Jun 2013 | Sep 2013 | Mar 2014 | Jun 2014 | Sep 2014 | Mar 2015 | Jun 2015 | Sep 2015 | Mar 2016 | Jun 2016 | Sep 2016 | Mar 2017 | Jun 2017 | Sep 2017 | Mar 2018 | Jun 2018 | Sep 2018 | Mar 2019 | Jun 2019 | Sep 2019 | Mar 2020 | Jun 2020 | Sep 2020 | Mar 2021 | Jun 2021 | Sep 2021 | Mar 2022 | Jun 2022 | Sep 2022 | Mar 2023 | Jun 2023 | Sep 2023 | Mar 2024 | Jun 2024 | Sep 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Mar 2026 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | - | - | - | - | - | - | - | - | - | - | - | - | - | 9.93B | 10.32B | 10.04B | 10.46B | 10.79B | 10.82B | 11.76B | 12.40B | 12.06B | 9.35B | 10.93B | 10.63B | 11.40B | 13.15B | 15.90B | 14.59B | 14.96B | 14.49B | 15.04B | 15.96B | 15.78B | 16.11B | 16.66B | 15.53B | 15.81B | 17.28B | 16.29B |
| Net Income | 1.59B | 906.00M | 1.12B | 1.71B | 2.00B | 895.00M | 953.00M | 687.00M | 1.83B | 1.12B | 1.21B | 2.18B | 1.55B | 1.95B | -56.00M | 736.00M | 1.71B | 1.95B | 2.92B | 2.67B | 1.90B | 3.22B | 3.00B | 2.94B | 3.18B | 1.54B | 4.57B | 4.31B | 3.94B | 3.25B | 2.82B | -5.97B | 4.75B | 4.76B | 5.46B | 3.16B | 5.08B | 4.43B | 5.79B | -4.24B |
| Diluted EPS | 0.52 | 0.30 | 0.38 | 0.57 | 0.68 | 0.31 | 0.33 | 0.24 | 0.64 | 0.40 | 0.43 | 0.78 | 0.56 | 0.71 | -0.02 | 0.27 | 0.63 | 0.73 | 1.12 | 1.03 | 0.74 | 1.26 | 1.18 | 1.16 | 1.25 | 0.61 | 1.80 | 1.70 | 1.55 | 1.28 | 1.11 | -2.35 | 1.86 | 1.87 | 2.14 | 1.24 | 2.01 | 1.76 | 2.32 | -1.72 |
| R&D Expense | 1.91B | 2.10B | 1.66B | 1.57B | 1.66B | 1.66B | 1.74B | 1.67B | 1.50B | 1.66B | 2.15B | 1.66B | 1.83B | 1.78B | 4.41B | 3.20B | 2.27B | 2.07B | 1.93B | 2.19B | 3.20B | 2.21B | 2.08B | 3.35B | 2.41B | 4.32B | 2.44B | 2.58B | 2.80B | 4.40B | 4.28B | 13.32B | 3.31B | 3.99B | 3.50B | 5.86B | 3.62B | 4.05B | 4.23B | 12.59B |
Profit & Loss (Annual)
Figures in USD.
| Metric | Dec 2007 | Dec 2008 | Dec 2009 | Dec 2010 | Dec 2011 | Dec 2012 | Dec 2013 | Dec 2014 | Dec 2015 | Dec 2016 | Dec 2017 | Dec 2018 | Dec 2019 | Dec 2020 | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 24.20B | 23.85B | 27.43B | 45.99B | 48.05B | 47.27B | 44.03B | 42.24B | 39.50B | 39.81B | 40.12B | 42.29B | 39.12B | 41.52B | 48.70B | 59.28B | 60.12B | 64.17B | 65.01B |
| Net Income | 3.28B | 7.81B | 12.90B | 861.00M | 6.27B | 6.17B | 4.40B | 11.92B | 4.44B | 3.92B | 2.39B | 6.22B | 9.84B | 7.07B | 13.05B | 14.52B | 365.00M | 17.12B | 18.25B |
| Diluted EPS | 1.49 | 3.63 | 5.65 | 0.28 | 2.02 | 2.00 | 1.47 | 4.07 | 1.56 | 1.41 | 0.87 | 2.32 | 3.81 | 2.78 | 5.14 | 5.71 | 0.14 | 6.74 | 7.28 |
| R&D Expense | 4.88B | 4.80B | 5.84B | 11.11B | 8.47B | 8.17B | 7.50B | 7.18B | 6.70B | 10.26B | 10.34B | 9.75B | 9.72B | 13.40B | 12.24B | 13.55B | 30.53B | 17.94B | 15.79B |
Balance Sheet (Annual)
Figures in USD.
| Metric | Dec 2006 | Dec 2007 | Dec 2008 | Dec 2009 | Dec 2010 | Dec 2011 | Dec 2012 | Dec 2013 | Dec 2014 | Dec 2015 | Dec 2016 | Dec 2017 | Dec 2018 | Dec 2019 | Dec 2020 | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Total Assets | - | - | 47.20B | 112.31B | 105.78B | 105.13B | 106.13B | 105.64B | 98.17B | 101.68B | 95.38B | 87.87B | 82.64B | 84.40B | 91.59B | 105.69B | 109.16B | 106.67B | 117.11B | 136.87B |
| Total Equity | 19.97B | 20.59B | 18.76B | 59.06B | 54.38B | 54.52B | 53.02B | 49.77B | 48.65B | 44.68B | 40.09B | 34.34B | 26.70B | 25.91B | 25.32B | 38.18B | 45.99B | 37.58B | 46.31B | 52.61B |
| Cash & Equivalents | 5.91B | 5.34B | 4.37B | 9.31B | 10.90B | 13.53B | 13.45B | 15.62B | 7.44B | 8.52B | 6.51B | 6.09B | 7.96B | 9.68B | 8.05B | 8.10B | 12.69B | 6.84B | 13.24B | 14.56B |
| Long Term Debt | - | - | 3.94B | 16.09B | 15.48B | 15.53B | 16.25B | 20.54B | 18.70B | 23.83B | 24.27B | 21.35B | 19.81B | 22.74B | 25.36B | 30.69B | 28.75B | 33.68B | 34.46B | 46.75B |
| Current Liabilities | - | - | 14.32B | 15.64B | 15.64B | 16.25B | 18.35B | 17.87B | 18.40B | 19.20B | 17.20B | 18.61B | 22.21B | 22.22B | 27.33B | 23.87B | 24.24B | 25.69B | 28.42B | 28.33B |
Cash Flows (Annual)
Figures in USD.
| Metric | Dec 2007 | Dec 2008 | Dec 2009 | Dec 2010 | Dec 2011 | Dec 2012 | Dec 2013 | Dec 2014 | Dec 2015 | Dec 2016 | Dec 2017 | Dec 2018 | Dec 2019 | Dec 2020 | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Operating Cash Flow | 7.00B | 6.57B | 3.39B | 10.82B | 12.38B | 10.02B | 11.65B | 7.99B | 12.54B | 10.38B | 6.45B | 10.92B | 13.44B | 10.25B | - | 19.09B | 13.01B | 21.47B | 16.47B |
| Investing Cash Flow | -2.81B | -1.83B | 3.16B | -3.50B | -2.89B | -6.80B | -3.15B | -374.00M | -4.76B | -3.21B | 2.68B | 4.31B | -2.63B | -9.44B | - | -4.96B | -14.08B | -7.73B | -13.74B |
| Financing Cash Flow | -4.87B | -5.52B | -1.64B | -5.44B | -6.90B | -3.27B | -5.99B | -15.24B | -5.39B | -9.04B | -10.01B | -13.16B | -8.86B | -2.83B | - | -9.12B | -4.81B | -7.03B | -1.92B |
| Capital Expenditure | - | - | - | - | - | - | - | - | - | - | - | - | - | - | -4.45B | -4.39B | -3.86B | -3.37B | -4.11B |
| Free Cash Flow | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | 14.71B | 9.14B | 18.10B | 12.36B |
| Share Buybacks | 1.43B | 2.73B | 0 | 1.59B | 1.92B | 2.59B | 6.52B | 7.70B | 4.19B | 3.43B | 4.01B | 9.09B | 4.78B | 1.28B | 840.00M | 0 | 1.35B | 1.31B | 5.08B |
Ratios (Annual)
Figures in %.
| Metric | Dec 2007 | Dec 2008 | Dec 2009 | Dec 2010 | Dec 2011 | Dec 2012 | Dec 2013 | Dec 2014 | Dec 2015 | Dec 2016 | Dec 2017 | Dec 2018 | Dec 2019 | Dec 2020 | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Gross Margin % | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
| Operating Margin % | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
| Net Margin % | 13.5% | 32.7% | 47.0% | 1.9% | 13.1% | 13.0% | 10.0% | 28.2% | 11.2% | 9.8% | 6.0% | 14.7% | 25.2% | 17.0% | 26.8% | 24.5% | 0.6% | 26.7% | 28.1% |
| ROE % | 15.9% | 41.6% | 21.8% | 1.6% | 11.5% | 11.6% | 8.8% | 24.5% | 9.9% | 9.8% | 7.0% | 23.3% | 38.0% | 27.9% | 34.2% | 31.6% | 1.0% | 37.0% | 34.7% |
| ROCE % | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
Shareholding Pattern
Top Institutional Holders
| # | Holder | % Held | Shares | Value |
|---|---|---|---|---|
| 1 | Blackrock Inc. | 9.14% | 225.83M | $28.47B |
| 2 | Vanguard Capital Management LLC | 6.52% | 160.99M | $20.30B |
| 3 | State Street Corporation | 4.83% | 119.33M | $15.04B |
| 4 | Wellington Management Group, LLP | 3.41% | 84.31M | $10.63B |
| 5 | Vanguard Portfolio Management LLC | 2.73% | 67.30M | $8.49B |
| 6 | Geode Capital Management, LLC | 2.41% | 59.56M | $7.51B |
| 7 | JPMORGAN CHASE & CO | 2.14% | 52.97M | $6.68B |
| 8 | Charles Schwab Investment Management, Inc. | 2.01% | 49.77M | $6.27B |
| 9 | Morgan Stanley | 1.93% | 47.63M | $6.01B |
| 10 | FMR, LLC | 1.80% | 44.52M | $5.61B |
Analyst View
Analyst aggregate. Targets and ratings update periodically; not investment advice.
Latest News
Recent headlines for MRK
Merck (MRK) Stock Looks Like A Bargain At This Price - Yahoo Finance
<a href="https://news.google.com/rss/articles/CBMimgFBVV95cUxNcEYtTEEwUmtVQ3NCclZUVXhHV3d5MHBxcEM4SVlCaENtUUhzQ1UzcWZSYm5fMHk4cEE3WnJvbGxMOGhqZWxrLUQtZzB1TnNLbXJtSEludk1iazdfYmZqZ3l4Y3ZjNk96Ylh0aTBMcWVVY0p6UWFGaGhjMGZYYmhYb2RRQVVaRGJCa2t4SX…
The $50B Plan Merck Stock Was Broadcasting - Trefis
<a href="https://news.google.com/rss/articles/CBMiowFBVV95cUxQQjA4Z2xnLUhtWFo1aWNYcjExM2c3dFRRcVZTTEdsNENFSFVuTks4a2NTbmZvV2JIekx2NGMyNlJNaVZfNUFuN3A2bUx6dWtvYzJmWjg3MF9xQUtHRDk2S0ZlS19uMmc0U1ZxZl9tb3JMaS12ZV9iN0NaRFNRdU9fQ2FOdWlBek5XTjR0Un…
Merck (MRK) Stock Sinks As Market Gains: Here's Why - Yahoo Finance
<a href="https://news.google.com/rss/articles/CBMimAFBVV95cUxNNV9EdHBwUUZjdllSRjRqb1Q1czFhNkJJRXViYUMwVzRrR2tkaTRpdUFDZjBTZUtPdmJiWFQzOFBPcHN3aTc0LXVmanJsTWlYeXB2VHN0b3B0MDBWS3FZT2FYdzM2eUJtd0R2ZE05MWJ2RjctUFMtbVVWc0RLSkV3cE1ySEljZXQxOXZacF…
BMO raises Merck stock price target to $142 on Keytruda Qlex uptake - Investing.com
<a href="https://news.google.com/rss/articles/CBMixAFBVV95cUxQdS00WTdpMTRRMUZsdnN3aEJscWNvVElheXZFVnVrTVlNdXlUWmZrYUx6YlZ1SmtGM2wtSmt2ZVBocHg2SHJ0aE5CMTZvQ2pEejk1dXd4QXY5SnZfeGRsZDZUSV9Yd3ptelpFX3ZhT1RRbTJaNXZqa0RXN203NmQ1cjRFcU5WcDJSdVFwal…
Why Merck Stock Is in the Spotlight Today - Benzinga
<a href="https://news.google.com/rss/articles/CBMipAFBVV95cUxNNFZnb044TzJnTUNXc3lFdmwzcVdoeHF0dkR2YkEtb2RrN3lhOTZoYmtzVUhDTTBjLTlxREx3bUhVS2M1T1l1X3B2OFJTNW4wbkw4bzlUU2g3cUdSRTE4M2hrZTRrM21lY2tDaXhyTFhJcjJicUUyRll6SHZ4Wmt5MVNVMXgyQktUYmxUVG…
Can Merck (MRK) Be A Bargain If Earnings Look Fair? - simplywall.st
<a href="https://news.google.com/rss/articles/CBMiwgFBVV95cUxObUFsemZWNXcyZjY3alJPRC1YZ0t4bFZ5T3JkVHFyOUNXU1FXTVVlM2xqN01DSThVMHhVdEthY2RjdFEwalVRZmlPMk53VHFaSGxKRTVkR2dhNk9JQURsVk9HSzlSaUdaejR2UFdsOUZIdjkyeUcwemstMlRKbmJKWGtLR3c4bmFTYm5VaE…
MRK — Frequently Asked Questions
What is the current share price of Merck & Co., Inc. (MRK)?
As of 2026-07-14 21:23 PDT, Merck & Co., Inc. (MRK) trades at $120.78 on NYSE. Its 52-week range is $75.59 to $129.56.
What is the market capitalisation of MRK?
Merck & Co., Inc. (MRK) has a market capitalisation of $298.31B on NYSE.
What is the P/E ratio of MRK?
MRK trades at a trailing price-to-earnings (P/E) ratio of 34.02. The industry average P/E is 25.41. Its price-to-book (P/B) ratio is 6.41.
Does MRK pay a dividend?
Merck & Co., Inc. (MRK) currently offers a dividend yield of 2.86%.
What is the return on equity (ROE) of MRK?
MRK has a return on equity (ROE) of 18.94%.
Is MRK a good stock to buy?
This page provides a data-driven analysis of Merck & Co., Inc. (MRK), including valuation ratios, profitability, growth trends, auto-generated pros and cons, peer comparison and AI exposure. Review these fundamentals alongside your own research and risk tolerance. This is informational content, not investment advice.